Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer’s disease

References

• Prince M, Ali GC, Guerchet M, et al. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther 2016;8:23.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Disease International. World Alzheimer Report 2015: The global impact of dementia: an analysis of prevalence, incidence, costs and trends. London: Alzheimer’s Disease International (ADI); 2015. Available at: https://www.alz.co.uk/research/world-report-2015
   Google Scholar
• Kumar A, Singh A. Ekavali A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 2015;67:195–203.
   PubMed Web of Science ®Google Scholar
• Berk C, Paul G, Sabbagh M. Investigational drugs in Alzheimer’s disease: current progress. Expert Opin Investig Drugs 2014;23:837–46.
   PubMed Web of Science ®Google Scholar
• Ozgeris B, Goksu S, Polat Kose L, et al. Acetylcholine-sterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds. Bioorg Med Chem 2016;24:2318–29.
   PubMed Web of Science ®Google Scholar
• Akincioglu A, Akincioglu H, Gulcin I, et al. Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: novel sulfamoylcarbamates and sulfamides derived from acetophenones. Bioorg Med Chem 2015;23:3592–602.
   PubMed Web of Science ®Google Scholar
• Gocer H, Akincioglu A, Goksu S, et al. Carbonic anhydrase and acetylcholinesterase inhibitory effects of carbamates and sulfamoylcarbamates. J Enzyme Inhib Med Chem 2015;30:316–20.
   PubMed Web of Science ®Google Scholar
• Bajda M, Guzior N, Ignasik M, Malawska B. Multi-target-directed ligands in Alzheimer’s disease treatment. Curr Med Chem 2011;18:4949–75.
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Rosini M, Andrisano V, et al. MTDL design strategy in the context of Alzheimer’s disease: from lipocrine to memoquin and beyond. Curr Pharm Design 2009;15:601–13.
   PubMed Web of Science ®Google Scholar
• Zemek F, Drtinova L, Nepovimova E, et al. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 2014;13:759–74.
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Kolaczkowski M, Bucki A, et al. Novel multi-target-directed ligands for Alzheimer’s disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation. Eur J Med Chem 2016;124:63–81.
   PubMed Web of Science ®Google Scholar
• Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: targeting the cholinergic System. Curr Neuropharmacol 2016;14:101–15.
   PubMed Web of Science ®Google Scholar
• Xie SS, Wang XB, Li JY, et al. Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer’s disease. Eur J Med Chem 2013; 64:540–53.
   PubMed Web of Science ®Google Scholar
• Hosoi M, Hori K, Konishi K, et al. Plasma cholinesterase activity in Alzheimer’s disease. Neurodegener Dis 2015;15:188–90.
   PubMed Web of Science ®Google Scholar
• Garcia-Ayllon MS, Riba-Llena I, Serra-Basante C, et al. Altered levels of acetylcholinesterase in Alzheimer plasma. PloS One 2010;5:e8701.
   PubMed Web of Science ®Google Scholar
• Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer’s disease. Neurochem Res 2003;28:515–22.
   PubMed Web of Science ®Google Scholar
• Ballard CG, Greig NH, Guillozet-Bongaarts AL, et al. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2005;2:307–18.
   PubMedGoogle Scholar
• Holzgrabe U, Kapkova P, Alptuzun V, et al. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Tar 2007;11:161–79.
   PubMed Web of Science ®Google Scholar
• Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer’s disease therapy. Int Psychogeriatr 2002; 14:77–91.
   PubMed Web of Science ®Google Scholar
• Greig NH, Utsuki T, Yu Q, et al. A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001;17:159–65.
   PubMed Web of Science ®Google Scholar
• Ballard CG. Advances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64–70.
   PubMed Web of Science ®Google Scholar
• Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsycho-pharmacol 2006;9:101–24.
   PubMed Web of Science ®Google Scholar
• Eskander MF, Nagykery NG, Leung EY, et al. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer’s plaques and tangles. Brain Res 2005;1060:144–52.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin H, Zhu J, et al. Design, synthesis, in vitro and in vivo evaluation of tacrine-cinnamic acid hybrids as multi-target acetyl- and butyrylcholinesterase inhibitors against Alzheimer’s disease. RSC Adv 2017;7:33851–67.
   Web of Science ®Google Scholar
• Morris R. Developments of a water maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47–60.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun J, Huang Z, et al. Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer’s disease agents. Bioorg Med Chem 2013;21:2462–70.
   PubMed Web of Science ®Google Scholar
• Cheung J, Rudolph MJ, Burshteyn F, et al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 2012;55:10282–6.
   PubMed Web of Science ®Google Scholar
• Brus B, Kosak U, Turk S, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem 2014;57:8167–79.
   PubMed Web of Science ®Google Scholar
• DeLano WL. The PyMOL molecular graphics system. San Carlos (CA): DeLano Scientific; 2002. Available at: http://www.pymol.org
   Google Scholar
• Ellman GL, Courtney KD, Andres Jr V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Kam TI, Gwon Y, Jung YK. Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer’s disease. Cell Mol Life Sci 2014;71:4803–13.
   PubMed Web of Science ®Google Scholar
• Sohma Y. Medicinal chemistry focusing on aggregation of amyloid-β. Chem Pharm Bull 2016;64:1–7.
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 1996;16:881–91.
   PubMed Web of Science ®Google Scholar
• LeVine H. Thioflavine T interaction with synthetic Alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 1993;2:404–10.
   PubMed Web of Science ®Google Scholar